Medical News

RSS

New online resource to help people with Oral Mucositis launched

From today, a new resource is available to help people with Oral Mucositis: http://www.mouthsmadegood.com. Oral Mucositis (OM) is a side effect of cancer therapy and is characterised by a red, swollen and ulcerated mouth and tongue.

25 Jan 2010

Low-cost ventilators for healthcare emergencies

A group of UK anaesthetists have designed and tested three prototype low-cost ventilators that could provide vital support during major healthcare emergencies involving large numbers of patients or casualties. The devices, detailed in a paper published online by Anaesthesia, could also be used where resources are limited, such as in developing countries, remote locations or by the military.

25 Jan 2010

Proposal for NHI to be the most significant development in South Africa's healthcare sector in 2010

The proposal for a National Health Insurance (NHI) was without doubt the most significant development in South Africa's healthcare sector in 2010. The aim of the NHI is to create universal healthcare coverage for all the country's citizens.

25 Jan 2010

Research paves way for future vaccine against gastric adenocarcinoma

Despite a strong response from our immune defence, the body is unable to rid itself of the bacterium Helicobacter pylori. One reason for this is that this bacterium encourages elements of the immune response to remain in tissue, activating the wrong immune cells. Research results that pave the way for a future vaccine are now being published by the Sahlgrenska Academy at the University of Gothenburg, Sweden.

25 Jan 2010

Self-treatment for back pain: Sensory motor learning

Many people with back pain do not know what is causing it and they do not receive effective treatment, but learning to move in a more integrated way makes a big difference, reveals research from the Sahlgrenska Academy at the University of Gothenburg, Sweden.

25 Jan 2010

IntegraGen now offers Fluidigm's IFC technology to French researchers

Fluidigm, the inventor of integrated fluidic circuits (IFCs), has joined with IntegraGen SA, one of France’s leading providers of genetic research testing services, to bring IFC technology to French researchers. IntegraGen will offer premium class services to its customers using the Fluidigm BioMark™ System for Genetic Analysis and the Access Array™ sample preparation system for next-generation sequencing. IntegraGen’s lab will also be a demonstration site for researchers investigating Fluidigm’s technology.

25 Jan 2010

Halozyme Therapeutics and BioAtla sign research collaboration agreement

Halozyme Therapeutics, Inc., a biopharmaceutical company developing and commercializing products targeting the extracellular matrix, today announced the signing of an exclusive, worldwide, contract research collaboration agreement with BioAtla, LLC for the development of novel high throughput recombinant protein screening libraries directed against targets in oncology, aesthetic dermatology and inflammation.

25 Jan 2010

Biogen Idec and Swedish Orphan Biovitrum commence dosing in rFIXFc Phase I/IIa trial for hemophilia B

Biogen Idec and Swedish Orphan Biovitrum today announced that the first patient was dosed in a registrational, open-label, multicenter trial designed to evaluate the safety, pharmacokinetics and efficacy of the companies’ long-acting, recombinant Factor IX Fc fusion protein (rFIXFc) in hemophilia B patients.

25 Jan 2010

Elan Drug Technologies issues statement on FDA approval of AMPYRA

Elan Drug Technologies, a business unit of Elan Corporation, plc (NYSE: ELN) today issued the following statement regarding the U.S. Food and Drug Administration (FDA) approval of AMPYRA™ (dalfampridine) as a treatment to improve walking in patients with multiple sclerosis (MS).

25 Jan 2010

AMT reaches another milestone in the official marketing authorisation process for Glybera

Amsterdam Molecular Therapeutics, a leader in the field of human gene therapy, has reached another important milestone in the official marketing authorisation process for its lead product Glybera(R), AMT's proprietary product for lipoprotein lipase deficiency (LPLD).

25 Jan 2010

Reproductive coercion and partner violence increase risk of unintended pregnancy

Young women and teenage girls often face efforts by male partners to sabotage birth control or coerce pregnancy - including damaging condoms and destroying contraceptives - and these efforts, defined as "reproductive coercion," frequently are associated with physical or sexual violence, a study by a team of researchers led by UC Davis has found.

25 Jan 2010

Ambidextrous children more likely to have ADHD symptoms

Children who are mixed-handed, or ambidextrous, are more likely to have mental health, language and scholastic problems in childhood than right- or left-handed children, according to a new study published today in the journal Pediatrics.

25 Jan 2010

Dermatological nuisance caused by toilet seats making a comeback in pediatricians' offices

Considered a dermatological nuisance that was long gone, skin irritations caused by toilet seats appear to be making a comeback in pediatricians' offices, according to research led by Johns Hopkins Children's Center investigator Bernard Cohen, M.D.

25 Jan 2010

Prostate cancer: Surgery in county hospitals, radiation or hormone therapy in private facilities

Researchers at Moores Cancer Center at the University of California, San Diego and colleagues have found that prostate cancer treatments varied significantly between county hospitals and private providers. Patients treated in county hospitals are more likely to undergo surgery while patients treated in private facilities tend to receive radiation or hormone therapy. These findings were published online by the journal Cancer on January 25.

25 Jan 2010

Bill Gates' annual letter highlights innovations aimed at combating disease, hunger and poverty

Bill Gates, co-chair of the Bill & Melinda Gates Foundation, today released his second annual letter -- a personal appraisal of the foundation's efforts to date and how innovation impacts priorities of the foundation.

25 Jan 2010

Dr. Reddy's gains access to Aegis' Intravail drug delivery technology for undisclosed therapeutics

Dr. Reddy's Laboratories (NYSE: RDY) and Aegis Therapeutics, LLC (Aegis) today announced a partnership providing Dr. Reddy's access to Aegis' Intravail® drug delivery technology for certain undisclosed therapeutics currently being marketed with annual worldwide sales in excess of U.S. $1 billion. Financial terms were not disclosed.

25 Jan 2010

Labeled menus may lead to reduced calorie intake in children

In a new study, the amount of calories selected by parents for their child's hypothetical meal at McDonald's restaurants were reduced by an average of 102 calories when the menus clearly showed the calories for each item. This is the first study to suggest that labeled menus may lead to significantly reduced calorie intake in fast food restaurant meals purchased for children.

25 Jan 2010

SEIU proposes a 44% increase in companies’ contributions to family health care coverage

First, these janitors are paid significantly higher wages and benefits than their counterparts in other major Midwestern cities. Second, their compensation package includes excellent health care coverage for which they pay less than 6% of the costs. Third, the union proposed un-affordably high pay increases in excess of 15% and other significant benefit changes, including, for example, a 44% increase in the companies’ contributions to family health care coverage.

25 Jan 2010

Former union officials attempt to stop 29 elections

After months and months of saying they wanted union elections held immediately at hospitals and nursing homes in California, former SEIU-UHW officials who were ousted from the union are now trying to stop 29 elections that are ready to proceed for more than 4,000 workers.

24 Jan 2010

Erbitux improves survival of mCRC patients with KRAS wild-type tumors

Merck Serono, a division of Merck KGaA, Darmstadt, Germany, today announced that Erbitux® (cetuximab) provided an improvement in overall survival (OS) when added to the standard 1st-line FOLFIRI chemotherapy regimen for metastatic colorectal cancer (mCRC) patients with KRAS wild-type tumors in the CRYSTAL study.

24 Jan 2010

Medical News

New online resource to help people with Oral Mucositis launched

Low-cost ventilators for healthcare emergencies

Proposal for NHI to be the most significant development in South Africa's healthcare sector in 2010

Research paves way for future vaccine against gastric adenocarcinoma

Self-treatment for back pain: Sensory motor learning

IntegraGen now offers Fluidigm's IFC technology to French researchers

Halozyme Therapeutics and BioAtla sign research collaboration agreement

Biogen Idec and Swedish Orphan Biovitrum commence dosing in rFIXFc Phase I/IIa trial for hemophilia B

Elan Drug Technologies issues statement on FDA approval of AMPYRA

AMT reaches another milestone in the official marketing authorisation process for Glybera

Reproductive coercion and partner violence increase risk of unintended pregnancy

Ambidextrous children more likely to have ADHD symptoms

Dermatological nuisance caused by toilet seats making a comeback in pediatricians' offices

Prostate cancer: Surgery in county hospitals, radiation or hormone therapy in private facilities

Bill Gates' annual letter highlights innovations aimed at combating disease, hunger and poverty

Dr. Reddy's gains access to Aegis' Intravail drug delivery technology for undisclosed therapeutics

Labeled menus may lead to reduced calorie intake in children

SEIU proposes a 44% increase in companies’ contributions to family health care coverage

Former union officials attempt to stop 29 elections

Erbitux improves survival of mCRC patients with KRAS wild-type tumors

Bioprocess Efficiency with Cell Density Monitoring

Exploring electron microscopy for plant and microbial imaging at the John Innes Centre

Extending the reach of Amperia™

Latest News